Industry News
Researchers discover how cell dark matter may drive cancer
Oct 07, 2013
University of Montreal researchers have discovered how telomerase, a molecule essential for cancer development, is directed to structures on our genome called telomeres in order to maintain its integrity and in turn, the integrity of the genome... Read More
Sieving through 'junk' DNA reveals disease-causing genetic mutations
Oct 07, 2013
Researchers can now identify DNA regions within non-coding DNA, the major part of the genome that is not translated into a protein, where mutations can cause diseases such as cancer. Their approach reveals many potential genetic variants within non-coding DNA that drive the development of a variety of different cancers. This approach has great potential to find other disease-causing variants... Read More
Target for drug development identified for triple-negative breast cancer
Oct 07, 2013
Often deadly "triple-negative" breast cancers might be effectively treated in many cases with a drug that targets a previously unknown vulnerability in the tumors, according to a UC San Francisco researcher who described her discovery in a study published online in the journal Cancer Cell... Read More
Potential new drug identified for inherited cancer
Oct 06, 2013
Scientists from the Florida campus of The Scripps Research Institute (TSRI) have identified a new drug candidate for an inherited form of cancer with no known cure. The new study showed the drug candidate - known as FRAX97 - slowed the proliferation and progression of tumor cells in animal models of Neurofibromatosis type 2... Read More
Scientists Shed Light on Body's Master Energy Regulator
Oct 05, 2013
Scientists from the Florida campus of The Scripps Research Institute (TSRI) have discovered some key features that explain just what turns on a protein that is considered to be a master regulator of how the human body uses and stores energy... Read More
Prostate cancer screenings: high Medicare spending but little benefit for older men
Oct 04, 2013
Prostate cancer screening has little benefit for men aged 75 and older, yet over three years, the Medicare fee-for-service program spent $447 million annually on PSA-based screenings - one-third of which was for men in the over 75 age group, according to study by researchers at the Yale Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center. Published in the Oct... Read More
Prostate cancer screenings: high Medicare spending but little benefit for older men
Oct 04, 2013
Prostate cancer screening has little benefit for men aged 75 and older, yet over three years, the Medicare fee-for-service program spent $447 million annually on PSA-based screenings - one-third of which was for men in the over 75 age group, according to study by researchers at the Yale Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center. Published in the Oct... Read More
NIH grant could develop technology to help personalize leukemia treatments
Oct 04, 2013
People affected by leukemia and health care professionals who advocate for personalized medicine options could benefit from technology that is being developed with funding from a National Institutes of Health grant. Tymora Analytical Operations LLC, Purdue University and St. Jude Children's Research Hospital have been awarded a one-year, $300,000 Phase I STTR grant from the NIH... Read More
Nottingham Hospitals in world first with Apple iPod blood-tracking
Oct 04, 2013
Hospitals in Nottingham will become the first in the world to take advantage of an electronic blood-tracking system allowing nurses to use Apple iPods at the bedside. Nottingham University Hospitals NHS Trust has agreed the deal with leading healthcare technology company MSoft eSolutions to implement the technology at Nottingham City Hospital and Queen's Medical Centre... Read More
Genetic anti-inflammatory defect predisposes children to lymphoma
Oct 04, 2013
New research shows that children with an inherited genetic defect in a critical anti-inflammatory pathway have a genetic predisposition to lymphoma... Read More
Previous Page Next Page